The Art of Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Art of Investing

PICK 51.06

+2.3%

Dec 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sun Tzu who wrote (10451)	10/29/2025 5:00:29 PM
From: Sun Tzu	of 10712

Guardant Health Q3 revenue up 39%, beats estimates Oct 29, 2025, 16:24 GMT-4Refinitiv1 min read GH+3.87% Overview Guardant Health Q3 revenue grows 39% yr/yr, beating analyst expectations Adjusted loss per share for Q3 beats consensus, reflecting operational improvements Company raises 2025 revenue guidance to $965-$970 mln, indicating strong growth outlook Outlook Guardant Health raises 2025 revenue guidance to $965-$970 mln, up from $915-$925 mln Company expects 2025 oncology revenue to grow 25% year-over-year Screening revenue for 2025 expected between $71-$73 mln, driven by Shield tests Result Drivers ONCOLOGY TEST VOLUME - Co attributes 40% growth in oncology test volume to strong performance across Guardant360 Liquid, Tissue, and Reveal tests SCREENING REVENUE - Shield screening tests generated $24.1 mln in revenue, marking significant growth from $1 mln in prior year period STRATEGIC COLLABORATIONS - Co established partnerships with Quest Diagnostics and PathGroup to expand Shield access nationwide

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next